Eli Lilly and Company
Eli Lilly and Company
- Market cap
- $1.70T
- P/E ratio
- 44.92
Your view on LLY.TO
Overview
What the company does, where it operates, and who runs it.
About Eli Lilly and Company
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- David A. Ricks
- Headquarters
- P.O. Box 73, Exchange Tower 130 King Street West, Suite 900, Indianapolis, IN, US
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- CEO
- David A. Ricks
- Headquarters
- P.O. Box 73, Exchange Tower 130 King Street West, Suite 900, Indianapolis, IN, US
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Eli Lilly and Company. Starting points for Eli Lilly and Company: P/E 44.9, EPS C$30.92, beta 1.19 — an Drug Manufacturers - General name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Eli Lilly and Company. Eli Lilly and Company paid C$0.25 per share over the last year — a 0.5% yield at the current C$49.16 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Eli Lilly and Company. Trailing twelve-month EPS for Eli Lilly and Company stands at C$30.92. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Eli Lilly and Company. Eli Lilly and Company has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| JNJJohnson & Johnson | Healthcare | NYSE | $656.5B | ||
| LLYEli Lilly and Company | Healthcare | NYSE | $1.3T | ||
| MIRAMIRA Pharmaceuticals, Inc. | Healthcare | NASDAQ | $24.8M | ||
| MRKMerck & Co., Inc. | Healthcare | NYSE | $339.7B | ||
| NONOFNovo Nordisk A/S | Healthcare | OTC | $168.6B | ||
| NVONovo Nordisk A/S | Healthcare | NYSE | $173.8B | ||
| NVSNovartis AG | Healthcare | NYSE | $293.1B | ||
| NVSEFNovartis AG | Healthcare | OTC | $316.8B | ||
| OGNOrganon & Co. | Healthcare | NYSE | $3.7B | ||
| OPHLFOno Pharmaceutical Co., Ltd. | Healthcare | OTC | $7.8B | ||
| OPHLYOno Pharmaceutical Co., Ltd. | Healthcare | OTC | $7.9B | ||
| ORINFOrion Oyj | Healthcare | OTC | $11.1B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| PBPHPortfolio Building Block World Pharma and Biotech Index ETF | $1.4B in assets | 16.94% | |
| TGRTT. Rowe Price Growth ETF | $1.6B in assets | 3.54% | |
| DXG.TODynamic Active Global Dividend ETF | $825M in assets | 1.93% | |
| VUN.TOVanguard U.S. Total Market Index ETF | $20.1B in assets | 0.00% | |
| DXU.TODynamic Active U.S. Dividend ETF | $85M in assets | 3.80% | |
| VEQT.TOVanguard All-Equity ETF Portfolio | $17.6B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in LLY.TO.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Eli Lilly and Company. Coverage tracks Eli Lilly and Company within Drug Manufacturers - General (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Eli Lilly and Company.